PR-positive breast cancer: Tumor cells express progesterone receptors, usually indicating a functional estrogen receptor pathway. Often associated with better prognosis and predicts benefit from endocrine therapy (tamoxifen, aromatase inhibitors, fulvestrant).
Key for pharmacists: PR positivity strengthens the case for hormonal therapy; PR negativity in an ER+ tumor may suggest a less favorable response to endocrine treatment.
Synonyms
PR+, PR-positive breast cancer